How many clinical trials are there for Atypical Hemolytic-Uremic Syndrome?

PlainTrial tracks 4 US clinical trials for Atypical Hemolytic-Uremic Syndrome, of which 1 are currently recruiting.

Which interventions appear most often on Atypical Hemolytic-Uremic Syndrome trial records?

Crovalimab is the most-linked intervention name on Atypical Hemolytic-Uremic Syndrome records (2 trial links), followed by Iptacopan. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for Atypical Hemolytic-Uremic Syndrome?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Atypical Hemolytic-Uremic Syndrome: later-stage trial registry

Compiled by PlainTrial · August 8, 2026

1 of 4 indexed Atypical Hemolytic-Uremic Syndrome trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Atypical Hemolytic-Uremic Syndrome: 4 US clinical trials tracked, 1 recruiting.

Atypical Hemolytic-Uremic Syndrome is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 2 of these trials.

Enrollment posture brief

Registry condition atypical-hemolytic-uremic-syndrome

Volume-matched condition peers

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Open-enrollment share among volume-matched conditions near Atypical Hemolytic-Uremic Syndrome

Atypical Hemolytic-Uremic Syndrome lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Atypical Hemolytic-Uremic Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Atypical Hemolytic-Uremic Syndrome is recruiting below its size-band peers.

1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Open and recent trials

4 total, page 1 of 1

RECRUITING 3,000 participants

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Alexion Pharmaceuticals

NCT01522183

ACTIVE NOT RECRUITING Phase 3 83 participants

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Hoffmann-La Roche

NCT04861259

ACTIVE NOT RECRUITING Phase 3 41 participants

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Hoffmann-La Roche

NCT04958265

ACTIVE NOT RECRUITING Phase 3 34 participants

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Novartis Pharmaceuticals

NCT04889430

Phase Distribution

Phase	Trial count
Phase 3	3

Top Sponsors

Hoffmann-La Roche 2 trials

Alexion Pharmaceuticals 1 trials

Novartis Pharmaceuticals 1 trials

Named interventions

Most-linked intervention names on Atypical Hemolytic-Uremic Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Crovalimab Drug

2 trials

Iptacopan Drug

1 trials

US sites by state

Facility locations filed on Atypical Hemolytic-Uremic Syndrome trials. A trial with sites in several states counts in each.

Ohio 4 trials

Texas 3 trials

Colorado 3 trials

New Jersey 2 trials

North Carolina 2 trials

Missouri 2 trials

Massachusetts 2 trials

Georgia 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Atypical Hemolytic-Uremic Syndrome page

4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

1 Atypical Hemolytic-Uremic Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
Hoffmann-La Roche sponsors the most Atypical Hemolytic-Uremic Syndrome trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atypical Hemolytic-Uremic Syndrome condition card totals 4 registered trials; most-linked intervention Crovalimab; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.